Recent

% | $
Quotes you view appear here for quick access.

BioTime, Inc. Message Board

  • btimnextmicrosoft btimnextmicrosoft Apr 19, 2013 9:12 AM Flag

    Another major University/hospital partnership for BTX regen therapeutics

    ....BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke....
    Adding to the list...TEVA, Cornel/Weil, UCLA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • They key thing to remember here is timing. The overall timing of Biotimes products are very good. Don't want to be one of these companies who patents early tech and then puts all there eggs in one product just to get dated within months.
      This industry is fast moving and so Dr. West is slowly cornering, genetic ip and cancer marker IP along with the rest of the stem cell IP. So that as the technology ripens Biotime will be right there at the forefront.

    • Cornell and UCLA have leading heart programs, Biotime is a keeper.

    • Proof BioTime’s HyStem hydrogels work.
      S. THOMAS CARMICHAEL, M.D., PH.D.:
      “I have used Hystem HP and Hystem C for selected applications in the delivery of neurotherapeutics in experimental stroke studies. These hydrogels have proven very flexible in their ability to slowly release small and large molecules and to support cell survival. The technical support from staff at Biotime has been excellent.”

      Here is what UCLA says about Biotimes Matrix IP:
      Stroke is the leading cause of adult disability. Stem or progenitor transplantation improves recovery in many pre-clinical stroke models. However, stem/progenitor therapies have not been translated to the clinic. At least three limitations have impacted the clinical utility or translation of stem/progenitor cell therapies in stroke: most of the transplanted cells die, the surviving cells often do not differentiate, and the direct injection of transplanted stem cells into the tissue adjacent to the stroke may produce damage at this site, which is the region of most repair and recovery in this disease. These limitations have established a translational bottleneck in stroke therapy. Tissue bioengineering approaches provide a possible solution to these problems. Work with self-assembling biopolymers or nanosystems provides an ability to link functionally important molecules for stem cell survival, such as extracellular matrix proteins, to stem cell or progenitor preparations within a pro-survival or pro-growth matrix. We have shown that such a preparation, a biopolymer hydrogel, allows stem cells to be transplanted directly into the stroke cavity.
      We have utilized hydrogels with extracellular matrix proteins as a matrix to support stem/progenitor transplantation into the stroke cavity after stroke (Zhong et al.). This matrix improves transplant survival and diminishes inflammatory attach on the transplant site.

    • Another one of biotimes 'picks & Shovels" being picked up by regen gold diggers!

 
BTX
3.00+0.02(+0.67%)Aug 26 4:00 PMEDT